NCT06184269

A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1017-1" and Co-administration of "BR1017-1A" and "BR1017-1B"

An Open-label, Randomized, Fasting, Single-dose, 2-sequence, 4-period, Crossover Phase 1 Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1017-1" and Co-administration of "BR1017-1A" and "BR1017-1B" in Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 58 (actual)
• Sponsor: Boryung Pharmaceutical Co., Ltd · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Accepted

Summary

The objective of this clinical study is to evaluate the pharmacokinetics and the safety after administration of "BR1017-1" and co-administration of "BR1017-1A" and "BR1017-1B" in healthy volunteers

Conditions

• Essential Hypertension
• Primary Hypercholesterolemia

Interventions

Type	Name	Description
DRUG	BR1017-1	One tablet administered alone
DRUG	BR1017-1A	One tablet administered alone
DRUG	BR1017-1B	One tablet administered alone

Timeline

• Start date: 2023-12-23
• Primary completion: 2024-02-18
• Completion: 2024-02-18
• First posted: 2023-12-28
• Last updated: 2024-04-02

Locations

1 site across 1 country: South Korea